<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="81d75979-e503-486b-ae76-5f11252e694d" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-d7cfedf0-cb0d-4ba3-aa59-d6e54da4e933" mediaType="text/x-hl7-title+xml">Plasma-Lyte&#174; 148 and 5% Dextrose
        Injection<br />(Multiple Electrolytes and Dextrose Injection, Type 1, USP)<br />in Viaflex&#174;
        Plastic Container</title>
<effectiveTime value="20060413" />
<setId root="81d75979-e503-486b-ae76-5f11252e694d" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="DC7D38CB-03DE-AE7E-69BD-FBA8C891A451" />
<effectiveTime value="20060413" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0149" codeSystem="2.16.840.1.113883.6.69" />
<name>Plasma-Lyte 148 and dextrose</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="5">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="5" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Dextrose hydrous</name>
<activeMoiety>
<activeMoiety>
<code code="IY9XDZ35W2" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>dextrose</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="526">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="526" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="37">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="37" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="30">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="30" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Magnesium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Magnesium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="502">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="502" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="R6Q3791S76" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Gluconate</name>
<activeMoiety>
<activeMoiety>
<code code="R6Q3791S76" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium gluconate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="368">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="368" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Acetate</name>
<activeMoiety>
<activeMoiety>
<code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium acetate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Sodium chloride, potassium chloride, calcium chloride, sodium gluconate, sodium acetate and dextrose</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Hydrochloric acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0149-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator unit="mL" value="1000">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0149-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-d06d4770-ddf9-4ec2-b493-65a0edd30fa8">
<id root="6806FD29-1393-2A7C-8164-3E942FB7B0A0" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-6ebd6e44-b969-4f07-8612-ed0e6ba96219" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-99eaf1ac-fb18-48b6-a0ec-1f1dcc56c6b7"><paragraph ID="INV-d6a2aed0-bd7a-4185-9047-976ab9f43eb8">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) is a sterile, nonpyrogenic solution for fluid and            electrolyte replenishment and caloric supply in a single dose container
                            for intravenous administration. Each 100 mL contains 5 g Dextrose
                            Hydrous, USP*, 526 mg Sodium Chloride, USP (NaCl); 502 mg Sodium
                            Gluconate (C<sub>6</sub>H<sub>11</sub>NaO<sub>7</sub>); 368 mg Sodium
                            Acetate Trihydrate, USP
                                (C<sub>2</sub>H<sub>3</sub>NaO<sub>2</sub>&#8226;3H<sub>2</sub>O), 37 mg
                            Potassium Chloride, USP (KCl); and 30 mg Magnesium Chloride, USP
                                (MgCl<sub>2</sub>&#8226;6H<sub>2</sub>O). It contains no antimicrobial
                            agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted with hydrochloric
                            acid.</paragraph><renderMultiMedia referencedObject="MM-f9af8afa-748c-40ee-86f1-8797f2f8895b" /><paragraph ID="INV-ce2f0e17-8a88-4f71-8979-ac8d247789fc">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) administered intravenously has value as a source of water,
                            electrolytes, and calories. One liter has an ionic concentration of 140
                            mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq
                            acetate and 23 mEq gluconate. The osmolarity is 547 mOsmol/L (calc).
                            Normal physiologic osmolarity range is approximately 280 to 310                        mOsmol/L. Administration of substantially hypertonic solutions (&#8805; 600
                            mOsmol/L) may cause vein damage. The caloric content is 190 kcal/L.</paragraph><paragraph ID="INV-f12dbce8-2436-44fd-afaf-cfb0cc8f04e9">The Viaflex&#174;
                            plastic container is fabricated from a specially formulated polyvinyl              chloride (PL 146&#174; Plastic). The amount of water that can permeate from
                            inside the container into the overwrap is insufficient to affect the
                            solution significantly. Solutions in contact with the plastic container
                            may leach out certain chemical components from the plastic in very small
                            amounts; however, biological testing was supportive of the safety of the
                            plastic container materials.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<observationMedia ID="MM-f9af8afa-748c-40ee-86f1-8797f2f8895b">
<value mediaType="image/jpeg"><reference value="Plasma-017451.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-cc82b8d6-d160-4bb4-94bc-6630d94270cb">
<id root="C112F7AC-2F16-CACE-418D-ECD5A2E48A67" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-2de702b3-47d5-46e9-b954-a86e97256fe5" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-5d8b5c23-99d4-4938-a207-a05cf712a8ec"><paragraph ID="INV-d087be0b-ed3e-48e3-855f-8b4955839a1f">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) has value as a source of water, electrolytes, and calories.                    It is capable of inducing diuresis depending on the clinical condition
                            of the patient.</paragraph><paragraph ID="INV-3ed0fa3e-4074-4fa0-bed9-917e1cc1c371">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) produces a metabolic alkalinizing effect. Acetate and
                            gluconate ions are metabolized ultimately to carbon dioxide and water,
                            which requires the consumption of hydrogen cations.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-5f430673-d116-48de-b9f4-2bc5e70b8209">
<id root="7EC9524C-C846-0700-534D-B5D5DC53D9EA" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-15ebd297-0ec2-43c8-b449-633c8eaa2e76" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-48d7210d-b97d-491a-8a6c-c1404c9ea032"><paragraph ID="INV-a5559bff-cbca-4be5-b070-cb17d53ada0e">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) is indicated as a source of water, electrolytes, and
                            calories, or as an alkalinizing agent.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-bdf2add9-511d-49e9-83c2-ebfb29f231b5">
<id root="D612DB0A-AD52-F192-3B24-778CE3B9578F" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-dad0d357-b849-4402-832b-0b1381fb1ef8" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-3e8bb7c8-b732-481f-892c-13d86e73aaf9"><paragraph ID="INV-e21f4760-bee5-4f6f-9202-af6b71610b3e">Solutions                   containing dextrose may be contraindicated in patients with known
                            allergy to corn or corn products.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-b9fb38af-9026-4db2-982e-15ca113e68ca">
<id root="5A634EFC-7E77-A469-B731-FCECDFC9419E" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-ebbe1d44-27df-4961-b0aa-4b6fc3b10f82" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-513dfd29-9617-4042-a050-3fc01497206f"><paragraph ID="INV-8e1f06f2-ee00-4c66-b9ee-8d0396ecf6e7">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) should be used with great care, if at all, in patients with
                            congestive heart failure, severe renal insufficiency and in clinical
                            states in which there exists edema with sodium retention.</paragraph><paragraph ID="INV-e4e3160a-d90b-401c-8c3d-bef8bc98e354">Plasma-Lyte&#174; 148             and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) should be used with great care, if at all, in patients with
                            hyperkalemia, severe renal failure and in conditions in which potassium
                            retention is present.</paragraph><paragraph ID="INV-6c73dda2-76c4-451a-b361-edac377c6b6d">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) should be used with great care in patients with metabolic
                            or respiratory alkalosis. The administration of acetate or gluconate
                            ions should be done with great care in those conditions in which there                 is an increased level or an impaired utilization of these ions, such as
                            severe hepatic insufficiency.</paragraph><paragraph ID="INV-00e1ebc4-0c9f-4a43-bf19-b61cf3c39e06">The intravenous
                            administration of Plasma-Lyte&#174; 148 and 5% Dextrose Injection (Multiple           Electrolytes and Dextrose Injection, Type 1, USP) can cause fluid and/or
                            solute overloading resulting in dilution of serum electrolyte
                            concentrations, overhydration, congested states, or pulmonary edema. The
                            risk of dilutional states is inversely proportional to the electrolyte
                            concentrations of the injection. The risk of solute overload causing
                            congested states with peripheral and pulmonary edema is directly
                            proportional to the electrolyte concentrations of the injection.</paragraph><paragraph ID="INV-a7afb1fb-d793-4166-b471-da878d715b45">In patients with
                            diminished renal function, administration of Plasma-Lyte&#174; 148 and 5%
                            Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type
                            1, USP) may result in sodium or potassium retention.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-bc3418c3-67de-4542-ae87-33a4b313ce09">
<id root="E0A15AD9-DA87-F3C1-6E87-B7AC6F018037" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-9cc467f1-1a49-45cc-92a3-072662f6b254" mediaType="text/x-hl7-title+xml">GENERAL PRECAUTIONS</title>
<text ID="INV-bc379c97-e65f-4f59-a402-1d1cc55eec31"><paragraph ID="INV-09566f52-7d95-476f-a38d-9391045888c5">Clinical evaluation
                            and periodic laboratory determinations are necessary to monitor changes
                            in fluid balance, electrolyte concentrations and acid base balance
                            during prolonged parenteral therapy or whenever the condition of the
                            patient warrants such evaluation.</paragraph><paragraph ID="INV-b281823a-3607-4d0b-a4ac-80d5c33632cd">Plasma-Lyte&#174; 148                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) should be used with caution. Excess administration may
                            result in metabolic alkalosis.</paragraph><paragraph ID="INV-80c29e30-2d98-49a6-8976-e07421e5db80">Caution must be
                            exercised in the administration of Plasma-Lyte&#174; 148 and 5% Dextrose
                            Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to
                            patients receiving corticosteroids or corticotropin.</paragraph><paragraph ID="INV-ca82221d-0f50-4740-8f55-27f755e685f9">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) should be used with caution in patients with overt or
                            subclinical diabetes mellitus.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<section ID="INV-1d3f5909-96cf-43db-8c7d-de32723e265e">
<id root="23BEDEFF-F9F2-A4C1-9213-65A6D879667E" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-a4c3ce87-911e-404a-9fe2-17cb86ea9cb5" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060413" />
<component>
<section ID="INV-c41f3e5b-6962-4bda-b1d9-331000d95d7c">
<id root="67D07824-EF52-9DD6-CDE2-755C22B60DA4" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-ee4f849f-f1ef-4f97-8624-b6ebdbc4d1c4" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<effectiveTime value="20060413" />
<component>
<section>
<id root="C10641A9-2ABD-8FE6-7E5D-BDD01B5C7F89" />
<title ID="INV-7b486d46-2dd0-4acf-81ac-47ebef2fb204" mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text ID="INV-05462d66-3399-4f64-b9af-325a48cdc1cf"><paragraph ID="INV-ebb89c99-9489-46ad-a8c5-c67a115044b4">Animal reproduction studies have not been
                                                  conducted with Plasma-Lyte&#174; 148 and 5% Dextrose
                                                  Injection (Multiple Electrolytes and Dextrose
                                                  Injection, Type 1, USP). It is also not known
                                                  whether Plasma-Lyte&#174; 148 and 5% Dextrose
                                                  Injection (Multiple Electrolytes and Dextrose
                                                  Injection, Type 1, USP) can cause fetal harm
                                                  when administered to a pregnant woman or can
                                                  affect reproduction capacity. Plasma-Lyte&#174; 148
                                                  and 5% Dextrose Injection (Multiple Electrolytes
                                                  and Dextrose Injection, Type 1, USP) should be
                                                  given to a pregnant woman only if clearly
                                                  needed.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-038ab0e1-deca-4473-ae95-90b9a02322f4">
<id root="9E883FE9-17A4-4B4D-CFB7-10D0687D2FD1" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-34a93ebd-d367-4cc3-a394-09471ba3c72e" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-dce7f16e-59b6-41c9-9299-e1373e6a4cf1"><paragraph ID="INV-d248749c-f707-46c9-adda-94d27b04d210">Safety and
                                    effectiveness of Plasma-Lyte&#174; 148 and 5% Dextrose Injection
                                    (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in
                                    pediatric patients have not been established by adequate and
                                    well controlled trials, however, the use of plasmalyte and
                                    dextrose solutions in the pediatric population is referenced in
                                    the medical literature. The warnings, precautions and adverse
                                    reactions identified in the label copy should be observed in the
                                    pediatric population.</paragraph><paragraph ID="INV-42382870-bbb1-489d-a0c7-d547553372f8">In very low
                                    birth weight infants, excessive or rapid administration of
                                    dextrose injection may result in increased serum osmolality and
                                    possible hemorrhage.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-40ed5ba9-9c33-4261-96db-8f7e6e23b82a">
<id root="931DF413-50DA-E4F2-D801-60B85D085A66" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS                                 AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-ce55a68d-3a28-40d4-b366-aa52124a2de5" mediaType="text/x-hl7-title+xml">Carcinogenesis and
                                Mutagenesis and Impairment of Fertility</title>
<text ID="INV-43658dd0-1546-47a0-9f43-0c3fe9a33fac"><paragraph ID="INV-add08018-7a86-4b7b-9126-3640e591b32b">Studies
                                    with Plasma-Lyte&#174; 148 and 5% Dextrose Injection (Multiple
                                    Electrolytes and Dextrose Injection, Type 1, USP) have not been
                                    performed to evaluate carcinogenic potential, mutagenic
                                    potential, or effects on fertility.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-3c44de15-47fb-4a7d-ac8c-c5f4d606facf">
<id root="B26C8170-9D3D-1343-0508-39DA8ADFB48F" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-e178fcab-e5e3-4432-8a56-cc689c99baf3" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-222c042c-63d5-4cbb-b42f-c115e5f11e4e"><paragraph ID="INV-bc3fb293-0d26-44d1-9865-efc2e2082567">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when Plasma-Lyte&#174; 148 and 5% Dextrose Injection (Multiple
                                    Electrolytes and Dextrose Injection, Type 1, USP) is
                                    administered to a nursing mother.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-525a90d4-2777-4852-aff4-a19b155f7e1e">
<id root="5458F8E9-FBD1-A586-D7A4-289187E85C7C" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-9358cbb4-0c38-46eb-9fd8-8f628444e629" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-a48290b3-59e6-4e7d-8714-17871cd3bbe0"><paragraph ID="INV-b5241455-dc00-4d52-8f4c-f0ff9b0885ac">Clinical
                                    studies of Plasma-Lyte&#174; 148 and 5% Dextrose Injection (Multiple
                                    Electrolytes and Dextrose Injection, Type 1, USP) did not
                                    include sufficient numbers of subjects aged 65 and over to
                                    determine whether they respond differently from younger
                                    subjects. Other reported clinical experience has not identified
                                    differences in responses between the elderly and younger
                                    patients. In general, dose selection for an elderly patient
                                    should be cautious, usually starting at the low end of the
                                    dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or drug therapy.</paragraph><paragraph ID="INV-2afbfdfc-acb1-4c99-8acc-edaf07729b7d">Do not
                                    administer unless solution is clear and seal is
                                intact.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-8e8e5d27-6e1f-4803-b486-f60b211c9b3a">
<id root="B7E23FD6-88FB-0E97-F856-386B7CD90406" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-fd9f9944-0898-476c-a296-1cffedf67dc2" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-42b5b8ec-5d18-4d31-a40a-b2c950431dfa"><paragraph ID="INV-58026d87-fcab-4671-b781-9f41e15f4b8c">Reactions which may
                            occur because of the solution or the technique of administration include                 febrile response, infection at the site of injection, venous thrombosis
                            or phlebitis extending from the site of injection, extravasation and
                            hypervolemia.</paragraph><paragraph ID="INV-304c20c4-fffc-4db5-a08b-ba3e4c22c1d8">If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures, and save the
                            remainder of the fluid for examination if deemed necessary.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-5efe8f1e-b035-47cd-96aa-977a278b3801">
<id root="C3317F91-DAD1-1900-E46D-9D11B4892CD3" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-6ebf65fc-1c7f-460b-9f24-1423fa17cb84" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-3dceaa59-d9ec-4a93-bf81-a00edec604b1"><paragraph ID="INV-8c51773e-cc76-4faf-adab-2edd61095151">As directed by a
                            physician. Dosage is dependent upon the age, weight and clinical
                            condition of the patient as well as laboratory determinations.</paragraph><paragraph ID="INV-a4d10b61-5607-40c4-8d6d-8691a21b7083">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit.</paragraph><paragraph ID="INV-973cc813-9fd6-4f7a-a227-2386b2270be9">All injections in
                            Viaflex&#174; plastic containers are intended for intravenous administration
                            using sterile equipment.</paragraph><paragraph ID="INV-5be29494-06aa-49c0-9bd1-c80474eff912">As reported in the
                            literature, the dosage and constant infusion rate of intravenous
                            dextrose must be selected with caution in pediatric patients,
                            particularly neonates and low weight infants, because of the increased
                            risk of hyperglycemia/hypoglycemia.</paragraph><paragraph ID="INV-5c306924-42eb-4535-a98e-50743dee9afe">Additives may be
                            incompatible. Complete information is not available. Those additives
                            known to be incompatible should not be used. Consult with pharmacist, if
                            available. If, in the informed judgment of the physician, it is deemed
                            advisable to introduce additives, use aseptic technique. Mix thoroughly
                            when additives have been introduced. Do not store solutions containing
                            additives.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-379ed196-c464-4c82-85b1-89f3098d8666">
<id root="C9DDE6F9-A015-96F8-649F-4483C785C805" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-74990356-788f-45f8-ba15-bcb75b9538ab" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-58bc20e4-9999-42f8-8742-8c60e819cf40"><paragraph ID="INV-4d16d831-9f79-4dce-abff-2b9ee0376cc9">Plasma-Lyte&#174; 148
                            and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 1, USP) in Viaflex&#174; plastic containers is available as shown below:</paragraph><table frame="void"><col align="left" width="150pt" />
<col align="left" width="150pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="center" valign="top">Size                             (mL)</td><td align="center" valign="top">Code</td><td align="center" valign="top">NDC</td></tr>
<tr valign="top"><td align="center" valign="middle">1000</td><td align="center" valign="middle">2B2584</td><td align="center" valign="middle">NDC
                                        0338-0149-04</td></tr>
<tr valign="top"><td align="center" valign="middle">500</td><td align="center" valign="middle">2B2583</td><td align="center" valign="middle">NDC 0338-0149-03</td></tr>
</tbody>
</table><paragraph ID="INV-d6ce63ea-718e-4eae-aad6-b0e484e7b122">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. It is recommended the product be stored at room temperature                            (25&#176;C); brief exposure up to 40&#176;C does not adversely affect the
                        product.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-ca6c35fc-42f5-4444-aa4b-ee2bc3d42e16">
<id root="8045856E-F9D7-6872-EEFC-7E5A514C1E57" />
<code code="38056-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SUPPLEMENTAL PATIENT MATERIAL" />
<title ID="INV-0fe1703d-3038-4d2d-89f4-f4655fba7839" mediaType="text/x-hl7-title+xml">DIRECTIONS FOR USE OF
                        VIAFLEX&#174; PLASTIC CONTAINER</title>
<text ID="INV-e837daa2-34fb-46c4-89eb-87109bc0d911"><paragraph ID="INV-cd454685-3804-495f-82fe-7ec2c88b53e9"><content styleCode="bold">Warning:</content> Do not use plastic containers in
                            series connections. Such use could result in air embolism due to
                            residual air being drawn from the primary container before
                            administration of the fluid from the secondary container is
                        completed.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<section ID="INV-ffa9c965-72b9-479d-ac71-ac12d99a604c">
<id root="CAA45A90-A11C-0B4E-36D4-89AECAB9858A" />
<title ID="INV-a3266537-46a1-4e14-ad55-ccd6c9237370" mediaType="text/x-hl7-title+xml">To Open</title>
<text ID="INV-c01db87a-df66-4973-bc64-9bdb97850826"><paragraph ID="INV-aece6ffa-2c9c-4a82-9751-737f4642395c">Tear
                                    overwrap down side at slit and remove solution container. Some
                                    opacity of the plastic due to moisture absorption during the
                                    sterilization process may be observed. This is normal and does
                                    not affect the solution quality or safety. The opacity will
                                    diminish gradually. Check for minute leaks by squeezing inner             bag firmly. If leaks are found, discard solution as sterility
                                    may be impaired. If supplemental medication is desired, follow
                                    directions below.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="INV-52329cbb-fcec-42fb-960c-20d4761ac646">
<id root="BBCFC59F-F208-9568-90B3-0AB6C5B843FC" />
<title ID="INV-5798de1b-bfc8-4db9-ab51-1f4ab5bd3f90" mediaType="text/x-hl7-title+xml">Preparation for
                                Administration</title>
<text ID="INV-e738bb0c-d2e2-46f3-9c05-d2dd34e77623"><paragraph ID="INV-38bb5a70-61e7-4ed4-8785-047527c5033f">1. Suspend
                                    container from eyelet support.</paragraph><paragraph ID="INV-a5dc6347-f6b6-4df4-8c15-1332835140da">2. Remove
                                    plastic protector from outlet port at bottom of container.</paragraph><paragraph ID="INV-774e893c-1bd8-4781-810b-0f63891f20e1">3. Attach
                                    administration set. Refer to complete directions accompanying
                                    set.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component type="ActRelationship">
<section ID="INV-75fe5e74-9b02-4086-9595-8dc0bdd148aa" moodCode="EVN" type="ActHeir">
<id root="ACC028D2-F694-3217-2FAA-00F7202A1310" />
<title ID="INV-80402815-488d-4804-9e97-bcebc4a37966" mediaType="text/x-hl7-title+xml">To Add
                            Medication</title>
<effectiveTime value="20060413" />
</section>
</component>
<component type="ActRelationship">
<section ID="INV-a889be93-5b04-4084-b1d7-fb892e09ef59" moodCode="EVN" type="ActHeir">
<id root="5347BB7D-C2F3-06F4-56A7-CC1C6E731E82" />
<title ID="INV-8227ca92-148d-423a-9264-3150b2e49ea1" mediaType="text/x-hl7-title+xml">Warning:</title>
<text ID="INV-48f4342f-7d58-49d3-9f51-34fda0f00269"><paragraph ID="INV-abeb0ab1-42e3-4df1-a3f0-a8c2c6401d97">Additives                      may be incompatible.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component type="ActRelationship">
<section ID="INV-8d4c1796-cfa2-4133-a1da-829f54a019cd" moodCode="EVN" type="ActHeir">
<id root="B2B493BA-C248-E417-94F0-0FFC537C9855" />
<title ID="INV-d874d222-b566-4863-ac26-1bf26ddd1e01" mediaType="text/x-hl7-title+xml">To add medication
                                before solution administration</title>
<text ID="INV-e67cf8bc-9367-4ca5-acf9-d26fa71cc9ae"><paragraph ID="INV-70434c87-342b-4085-84ed-47ed62669262">1. Prepare
                                    medication site.</paragraph><paragraph ID="INV-63ae5a18-79a2-4c3a-b2e3-0a56226c74c4">2. Using
                                    syringe with 19 to 22 gauge needle, puncture resealable
                                    medication port and inject.</paragraph><paragraph ID="INV-f7d497c3-b0d2-4ee0-80b1-2aec9953a5ca">3. Mix
                                    solution and medication thoroughly. For high density medication
                                    such as potassium chloride, squeeze ports while ports are
                                    upright and mix thoroughly.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component type="ActRelationship">
<section ID="INV-11670341-3416-406f-9428-4307161cf468" moodCode="EVN" type="ActHeir">
<id root="B5A7E5CE-4AA3-4B02-461D-BFDBB86FACD7" />
<title ID="INV-4125f272-1c65-43c3-a3c7-4685a5deb5bd" mediaType="text/x-hl7-title+xml">To add medication
                                during solution administration</title>
<text ID="INV-6672fb7f-d09e-4fd7-9e11-6998d320f5a1"><paragraph ID="INV-3f1f5c5c-ae4a-4454-8b31-160ad8df3171">1. Close
                                    clamp on the set.</paragraph><paragraph ID="INV-11da16f2-09a5-460c-a99a-e47adae130ea">2. Prepare
                                    medication site.</paragraph><paragraph ID="INV-fbcc0286-d765-4d50-b9df-3a2663c36af1">3. Using                            syringe with 19 to 22 gauge needle, puncture resealable
                                    medication port and inject.</paragraph><paragraph ID="INV-a8885fec-a08a-49cd-8c87-17d6e1a9836b">4. Remove
                                    container from IV pole and/or turn to an upright position.</paragraph><paragraph ID="INV-dcf5ff8a-e37f-4d88-9ddf-d666597b81e1">5. Evacuate
                                    both ports by squeezing them while container is in the upright                 position.</paragraph><paragraph ID="INV-25c79afd-898a-4243-853a-2af0b5568e27">6. Mix
                                    solution and medication thoroughly.</paragraph><paragraph ID="INV-f1f2215a-4f24-437d-8648-f65d12b4ae3f">7. Return
                                    container to in use position and continue administration.</paragraph><paragraph ID="INV-a2cbc36d-acf2-4ac2-8c10-63ca05733805"><content styleCode="bold">Baxter Healthcare
                                    Corporation</content></paragraph><paragraph ID="INV-203f68c0-0194-4f8e-960e-c6f2448efaf8">Deerfield,
                                    IL 60015 USA</paragraph><paragraph ID="INV-392027d8-fdca-4a2a-98d3-5bfef09ecde5">Printed in
                                    USA</paragraph><paragraph ID="INV-919cc397-8587-4d3c-8f19-59ab11b7f588">&#169;Copyright
                                    1982, 1983, 1989, 1993, Baxter Healthcare Corporation.</paragraph><paragraph ID="INV-9b578b8c-e333-484e-8dad-e9ae49f229a4">All rights
                                    reserved.</paragraph><paragraph ID="INV-683fa822-9633-45a3-9188-427be5a7e6ef"><content styleCode="bold">7-19-22-968</content></paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
